caa a22 4500 465761887 CHVBK 20180323111901.0 cr unu---uuuuu 170327e19901201xx s 000 0 eng 10.1007/BF02987098 doi (NATIONALLICENCE)springer-10.1007/BF02987098 Carboplatin in combination with etoposide in inoperable non-small-cell lung cancer (NSCLC) [Elektronische Daten] [P. Weynants, Y. Humblet, A. Bosly, D. Schallier, P. Duprez, F. Majois, M. Beauduin, J. Prignot, M. Symann] Carboplatin, a second generation platinum complex, is less nephrotoxic and emetogenic than its parent compound. We have tested the objective response to and the toxicity of the combination carboplatin 330 mg m-2 on day 1 with etoposide 120 mg m-2 on days 1, 3 and 5, administered every 3 weeks in histologically proven inoperable non-small-cell lung cancer (NSCLC) patients with a good performance status. Thirty-one patients entered the study; 29 were evaluable for response, 24 after 3 courses and 5 after 2 courses of chemotherapy. An overall response rate of 21% was found including zero complete response and 6 partial responses. In addition, 3 minor responses (10%), 12 stable diseases (38%), and 9 progressive diseases (39%) were observed. The median survival was 48 weeks, including 68 weeks for non-metastatic (M0) patients and 27 weeks for metastatic (M + ) patients. This regimen was well tolerated. Gastrointestinal toxicity never exceeded WHO grade II and renal function remained in the normal range for all cases. Haematological toxicity was low in the majority of the cases; nevertheless it proved to be the dose limiting toxicity as illustrated by two grade III anemia, one grade III leucopenia, one grade III and one grade IV thrombocytopenia. Carboplatin-etoposide combination is not more active, but clearly much less toxic than cisplatin-etoposide in NSCLC. Humana Press Inc., 1990 Non-small-cell lung cancer nationallicence Carboplatin nationallicence Etoposide nationallicence Weynants P. UCL Clinical Oncology Group, Cliniques Universitaires St. Luc, 10 Avenue Hippocrate, 1200, Brussels, Belgium aut Humblet Y. UCL Clinical Oncology Group, Cliniques Universitaires St. Luc, 10 Avenue Hippocrate, 1200, Brussels, Belgium aut Bosly A. UCL Clinical Oncology Group, Cliniques Universitaires St. Luc, 10 Avenue Hippocrate, 1200, Brussels, Belgium aut Schallier D. Bristol Myers Benelux, Belgium aut Duprez P. UCL Clinical Oncology Group, Cliniques Universitaires St. Luc, 10 Avenue Hippocrate, 1200, Brussels, Belgium aut Majois F. UCL Clinical Oncology Group, Cliniques Universitaires St. Luc, 10 Avenue Hippocrate, 1200, Brussels, Belgium aut Beauduin M. UCL Clinical Oncology Group, Cliniques Universitaires St. Luc, 10 Avenue Hippocrate, 1200, Brussels, Belgium aut Prignot J. UCL Clinical Oncology Group, Cliniques Universitaires St. Luc, 10 Avenue Hippocrate, 1200, Brussels, Belgium aut Symann M. UCL Clinical Oncology Group, Cliniques Universitaires St. Luc, 10 Avenue Hippocrate, 1200, Brussels, Belgium aut Medical Oncology and Tumor Pharmacotherapy Humana Press 7/4(1990-12-01), 219-222 0736-0118 7:4<219 1990 7 12032 https://doi.org/10.1007/BF02987098 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF02987098 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Weynants P. UCL Clinical Oncology Group, Cliniques Universitaires St. Luc, 10 Avenue Hippocrate, 1200, Brussels, Belgium aut NATIONALLICENCE 700 1- Humblet Y. UCL Clinical Oncology Group, Cliniques Universitaires St. Luc, 10 Avenue Hippocrate, 1200, Brussels, Belgium aut NATIONALLICENCE 700 1- Bosly A. UCL Clinical Oncology Group, Cliniques Universitaires St. Luc, 10 Avenue Hippocrate, 1200, Brussels, Belgium aut NATIONALLICENCE 700 1- Schallier D. Bristol Myers Benelux, Belgium aut NATIONALLICENCE 700 1- Duprez P. UCL Clinical Oncology Group, Cliniques Universitaires St. Luc, 10 Avenue Hippocrate, 1200, Brussels, Belgium aut NATIONALLICENCE 700 1- Majois F. UCL Clinical Oncology Group, Cliniques Universitaires St. Luc, 10 Avenue Hippocrate, 1200, Brussels, Belgium aut NATIONALLICENCE 700 1- Beauduin M. UCL Clinical Oncology Group, Cliniques Universitaires St. Luc, 10 Avenue Hippocrate, 1200, Brussels, Belgium aut NATIONALLICENCE 700 1- Prignot J. UCL Clinical Oncology Group, Cliniques Universitaires St. Luc, 10 Avenue Hippocrate, 1200, Brussels, Belgium aut NATIONALLICENCE 700 1- Symann M. UCL Clinical Oncology Group, Cliniques Universitaires St. Luc, 10 Avenue Hippocrate, 1200, Brussels, Belgium aut NATIONALLICENCE 773 0- Medical Oncology and Tumor Pharmacotherapy Humana Press 7/4(1990-12-01), 219-222 0736-0118 7:4<219 1990 7 12032 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer